U.S. FDA Accepts sBLA for ENFLONSIA™ (clesrovimab-cfor) to Update its Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease Indication to Include Children Under Two Years at Increased Ri
Go back to U.S. FDA Accepts sBLA for ENFLONSIA™ (clesrovimab-cfor) to Update its Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease Indication to Include Children Under Two Years at Increased Ri| Merck & Co. (NYSE: MRK) | Delayed: 130.42 -0.5 (0.38%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $130.92 | 52 Week High | $65.46 | |||
| Open | $129.93 | 52 Week Low | $47.97 | |||
| Day High | $132.84 | P/E | 88.72 | |||
| Day Low | $129.70 | EPS | $1.47 | |||
| Volume | 6,343,840 | |||||
